The anti-Trop-2 antibody-drug conjugate Sacituzumab Govitecan-effectiveness, pitfalls and promises.
作者信息
Guerra Emanuela, Alberti Saverio
机构信息
Laboratory of Cancer Pathology, Center for Advanced Studies and Technology (CAST), University "G. D'Annunzio", Chieti, Italy.
Department of Medical, Oral and Biotechnological Sciences, University "G. D'Annunzio", Chieti, Italy.
出版信息
Ann Transl Med. 2022 May;10(9):501. doi: 10.21037/atm-22-621.
Abstract
摘要
相似文献
1
The anti-Trop-2 antibody-drug conjugate Sacituzumab Govitecan-effectiveness, pitfalls and promises.抗 Trop-2 抗体药物偶联物戈沙妥珠单抗——疗效、陷阱与前景
Ann Transl Med. 2022 May;10(9):501. doi: 10.21037/atm-22-621.
2
Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan.高表达人滋养细胞表面标志物（Trop-2）的宫颈癌对抗体药物偶联物 sacituzumab govitecan 高度敏感。
Sci Rep. 2020 Jan 22;10(1):973. doi: 10.1038/s41598-020-58009-3.
3
Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.Sacituzumab govitecan：一种新型抗体药物偶联物的过去、现在和未来及未来展望。
Future Oncol. 2022 Sep;18(28):3199-3215. doi: 10.2217/fon-2022-0407. Epub 2022 Sep 7.
4
Sacituzumab govitecan for hormone receptor-positive and triple-negative breast cancers.戈沙妥珠单抗用于激素受体阳性和三阴性乳腺癌
Mol Cell Pharmacol. 2023;15(1):1-5.
5
Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer.注射用戈沙妥珠单抗：一种用于治疗难治性、转移性三阴性乳腺癌的抗体药物偶联物。
Ann Pharmacother. 2021 Jul;55(7):921-931. doi: 10.1177/1060028020966548. Epub 2020 Oct 17.
6
Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan.靶向 TROP-2 并包含 SN-38 的抗体药物偶联物：抗 TROP-2 sacituzumab govitecan 的案例研究。
MAbs. 2019 Aug/Sep;11(6):987-995. doi: 10.1080/19420862.2019.1632115. Epub 2019 Jul 18.
7
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.Sacituzumab govitecan（IMMU-132），一种用于治疗多种上皮癌的抗 Trop-2-SN-38 抗体药物偶联物：安全性和药代动力学。
Cancer. 2017 Oct 1;123(19):3843-3854. doi: 10.1002/cncr.30789. Epub 2017 May 30.
8
Tackling metastatic triple-negative breast cancer with sacituzumab govitecan.使用 sacituzumab govitecan 治疗转移性三阴性乳腺癌。
Expert Rev Anticancer Ther. 2021 Dec;21(12):1303-1311. doi: 10.1080/14737140.2021.1993065. Epub 2021 Oct 22.
9
Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.注射用戈沙妥珠单抗：三阴性乳腺癌的突破性靶向治疗药物。
Expert Rev Anticancer Ther. 2019 Aug;19(8):673-679. doi: 10.1080/14737140.2019.1654378. Epub 2019 Aug 19.
10
Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer.戈沙妥珠单抗（Sacituzumab Govitecan）的临床前活性研究，这是一种靶向滋养层细胞表面抗原2（Trop-2）并与伊立替康活性代谢物（SN-38）偶联的抗体药物偶联物在卵巢癌中的研究。
Front Oncol. 2020 Feb 12;10:118. doi: 10.3389/fonc.2020.00118. eCollection 2020.
引用本文的文献
1
Last Resort? Rationale for Comprehensive Molecular Analysis in Treatment-Refractory R/M HNSCC: A Case Report of Remarkable Response to Sacituzumab Govitecan Following Molecular and Functional Characterization.最后的手段？难治性复发/转移性头颈部鳞状细胞癌综合分子分析的原理：一例在分子和功能特征分析后对戈沙妥珠单抗有显著反应的病例报告
Biomedicines. 2025 May 21;13(5):1266. doi: 10.3390/biomedicines13051266.
2
Exceptional response to TROP2 inhibition with sacituzumab govitecan in a patient with small cell carcinoma of the breast: a case report.一例小细胞乳腺癌患者使用戈沙妥珠单抗抑制TROP2后出现显著反应：病例报告
Ther Adv Med Oncol. 2025 Feb 26;17:17588359251322003. doi: 10.1177/17588359251322003. eCollection 2025.
3
Targeting Metabolic and Epigenetic Vulnerabilities in Glioblastoma with SN-38 and Rabusertib Combination Therapy.采用SN-38与瑞博西尼联合疗法靶向胶质母细胞瘤中的代谢和表观遗传脆弱性
Int J Mol Sci. 2025 Jan 8;26(2):474. doi: 10.3390/ijms26020474.
4
A Review of Current and Future Antibody Drug Conjugates in Breast Cancer.乳腺癌中当前及未来抗体药物偶联物综述
Curr Treat Options Oncol. 2024 Dec;25(12):1506-1516. doi: 10.1007/s11864-024-01276-3. Epub 2024 Nov 29.
5
Trop2-targeted therapies in solid tumors: advances and future directions.实体瘤中 Trop2 靶向治疗：进展与未来方向。
Theranostics. 2024 Jun 11;14(9):3674-3692. doi: 10.7150/thno.98178. eCollection 2024.
6
Antibody-Drug Conjugates in the Treatment of Genitourinary Cancers: An Updated Review of Data.抗体药物偶联物在泌尿生殖系统肿瘤治疗中的应用：数据更新综述。
Curr Oncol. 2024 Apr 19;31(4):2316-2327. doi: 10.3390/curroncol31040172.
7
Pioneering the Way: The Revolutionary Potential of Antibody-Drug Conjugates in NSCLC.开拓创新之路：抗体药物偶联物在 NSCLC 中的革命性潜力。
Curr Treat Options Oncol. 2024 Apr;25(4):556-584. doi: 10.1007/s11864-024-01196-2. Epub 2024 Mar 23.
8
Targeting Trop2 in solid tumors: a look into structures and novel epitopes.靶向实体瘤中的 Trop2：结构与新型表位研究
Front Immunol. 2023 Dec 20;14:1332489. doi: 10.3389/fimmu.2023.1332489. eCollection 2023.
9
Pesticides and Bladder Cancer: Mechanisms Leading to Anti-Cancer Drug Chemoresistance and New Chemosensitization Strategies.农药和膀胱癌：导致抗癌药物化疗耐药性的机制和新的化疗增敏策略。
Int J Mol Sci. 2023 Jul 13;24(14):11395. doi: 10.3390/ijms241411395.
10
The 2EF Antibody Targets a Unique N-Terminal Epitope of Trop-2 and Enhances the In Vivo Activity of the Cancer-Selective 2G10 Antibody.2EF抗体靶向Trop-2独特的N端表位并增强癌症选择性2G10抗体的体内活性。
Cancers (Basel). 2023 Jul 22;15(14):3721. doi: 10.3390/cancers15143721.
本文引用的文献
1
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.在晚期或转移性 HR+/HER2-和三阴性乳腺癌中应用德曲妥珠单抗偶联物：TROPION-PanTumor01 研究的 I 期结果。
J Clin Oncol. 2024 Jul 1;42(19):2281-2294. doi: 10.1200/JCO.23.01909. Epub 2024 Apr 23.
2
An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy.深入了解 FDA 批准用于癌症治疗的抗体药物偶联物。
Molecules. 2021 Sep 27;26(19):5847. doi: 10.3390/molecules26195847.
3
Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both?赛托珠单抗-戈维汀是作为传统抗体药物偶联物（ADC）、SN-38的前药，还是两者兼具？
Ann Transl Med. 2021 Jul;9(14):1113. doi: 10.21037/atm-21-1103.
4
Trop-2 induces ADAM10-mediated cleavage of E-cadherin and drives EMT-less metastasis in colon cancer.Trop-2 诱导 ADAM10 介导的 E-钙黏蛋白裂解，并驱动结肠癌 EMT 缺失转移。
Neoplasia. 2021 Sep;23(9):898-911. doi: 10.1016/j.neo.2021.07.002. Epub 2021 Jul 25.
5
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.在转移性三阴性乳腺癌患者中 sacituzumab govitecan 与化疗对比的 III 期 ASCENT 研究中的生物标志物分析。
Ann Oncol. 2021 Sep;32(9):1148-1156. doi: 10.1016/j.annonc.2021.06.002. Epub 2021 Jun 8.
6
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors.TROPHY-U-01 研究：在铂类化疗和检查点抑制剂治疗后进展的转移性尿路上皮癌患者中 sacituzumab govitecan 的 II 期开放标签研究。
J Clin Oncol. 2021 Aug 1;39(22):2474-2485. doi: 10.1200/JCO.20.03489. Epub 2021 Apr 30.
7
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.Sacituzumab Govitecan 治疗转移性三阴性乳腺癌。
N Engl J Med. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485.
8
Trop-2 cleavage by ADAM10 is an activator switch for cancer growth and metastasis.ADAM10 对 Trop-2 的裂解是促进肿瘤生长和转移的激活开关。
Neoplasia. 2021 Apr;23(4):415-428. doi: 10.1016/j.neo.2021.03.006. Epub 2021 Apr 8.
9
Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy.注射用戈沙妥珠单抗，一种新型第三代抗体药物偶联物（ADC），用于癌症治疗。
Expert Opin Biol Ther. 2020 Aug;20(8):871-885. doi: 10.1080/14712598.2020.1757067. Epub 2020 May 12.
10
Stable Isotope Dilution LC-HRMS Assay To Determine Free SN-38, Total SN-38, and SN-38G in a Tumor Xenograft Model after Intravenous Administration of Antibody-Drug Conjugate (Sacituzumab Govitecan).静脉注射抗体药物偶联物（Sacituzumab Govitecan）后肿瘤异种移植模型中游离 SN-38、总 SN-38 和 SN-38G 的稳定同位素稀释 LC-HRMS 测定法
Anal Chem. 2020 Jan 7;92(1):1260-1267. doi: 10.1021/acs.analchem.9b04419. Epub 2019 Dec 9.
Zotero 插件